examine whether statin therapy decreases the incidence of active TB in diabetic patients.
ulation. Logistic regression was then used to calculate the incidence of TB among matched groups. To observe the survival of diabetic patients to the incidence of TB between the number of months as a time variable, according to gender, age, co-morbidities (CCI) and statin cumulative definite daily dose (cDDD, low <28 vs medium 28-720 vs high dose >720) variables were divided into different groups and the Cox proportional hazards model was used to construct a survival regression model of diabetes.
Results: Matching of 11,998 diabetic patients yielded two cohort of 5999 patients, statin users and non-users. During the study period, 403 individuals were diagnosed with active TB. In comparison to non-TB patients, statin users were less frequent among TB patients (42.7% vs 57.3%, P < 0.001). Active TB protection increased with increasing dose of statin prescription. High dose statin users was associated with the lower risk of TB than medium dose (HR 0.643; 95% CI 0.614 to 0.744, P = 0.033). The effects estimates obtained for medium and low dose statin users were similar (HR 1.063; 95% CI 0.989 to 1.108, P = 0.606).
Conclusion:
Statin therapy among diabetic patients was associated with a protective effect on TB incidence, especially high dose. Background and Aims: High-throughput sequencing technology is widely used to find the unknown pathogens in cerebrospinal fluid, blood and so on. But it is controversial in bronchoalveolar lavage for pulmonary infectious diseases. The aim of this study was to investigate the diagnosis value of bronchoalveolar lavage detection by high-throughput sequencing for pulmonary infectious diseases.
Methods: We included patients with pulmonary infectious diseases or as control group from November 2017 to December 2017 in the department of respiratory disease, the third affiliated hospital of Sun Yat-sen University. High-throughput sequencing and culture of bronchoalveolar lavage fluid were used to evaluate the pathogens.
Results:
We included 14 patients, 12 cases were pulmonary infectious diseases and 2 cases were without pulmonary infectious diseases. High-throughput sequencing was fast (24h-48h) and expensive. The pathogens of 10 cases (71.4%) were confirmed by high-throughput sequencing, consistent with culture. At the same time, 9 cases (64.3%) showed not only one pathogen, which seemed lung microbiome detected by highthroughput sequencing. Some rare pathogens were found, containing some were difficult cultured, such as neurospora crassa OR74A, prevotella, treponema, human herpesvirus 5 and spirometra mansoni.
Conclusion: High-throughput sequencing was fast and expensive.
The bronchoalveolar lavage detection by high-throughput sequencing for pulmonary infectious diseases can help confirm the common pathogens, unknown pathogens or rare pathogens. It also helped to know the lung microbiome change of pulmonary infectious diseases. Results: Out of 210417 inpatients, there were 1472 (0.7%) HAP cases. 1158 cases were eventually included. The most common organisms were Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia. 188 cases were MDROs. The first logistic regression analysis identified the independent risk factors of MDROs-HAP included age, gender, encephalorrhagia, cerebral infarction, prior endotracheal tracheostomy, antibiotics therapy in the preceding 90 days, stomach tube intubation or gastrostomy, central venous catheterization, clinical pulmonary infection score>6, multi-lobular infiltration. In the second multivariable analysis that encephalorrhagia, cerebral infarction, prior endotracheal tracheostomy, antibiotics therapy in the preceding 90 days, stomach tube intubation, clinical pulmonary infection score>6, multilobular infiltration were still associated with MDROs-HAP. The therapy of MDROs was obviously with compliance to the guideline. The hospital stays were longer and 30-day mortality was worse with MDROs-HAP.
